Want to see CRNX full AI Analyst Report?
Top Page
Crinetics Pharmaceuticals
(NASDAQ:CRNX)
Select Model
Select Model
Rating:56Neutral
Price Target:
$87.00
▲(3.91% Upside)
Action:Reiterated
Date:08/20/26
The score is primarily constrained by weak financial performance driven by very large losses and significant ongoing cash burn, despite strong gross margins and rapid revenue growth. Technicals and the latest earnings call are supportive—uptrend strength plus early launch and reimbursement progress with multi-year cash runway—but valuation remains difficult to assess due to negative earnings and no dividend data.
Positive Factors
Early Commercial Traction
Early product revenue and enrollment growth show initial demand, while reimbursement and coverage gains can support repeatable adoption. The expanding prescriber base and treatment-naive use indicate the launch is building a broader commercial foundation.
Negative Factors
Large Losses and Cash Burn
Revenue growth has not translated into profitability: TTM losses and cash outflows remain very large. Continued development and launch spending create a substantial funding requirement and could erode equity or require additional capital if burn persists.
Read all positive and negative factors
Positive Factors
Negative Factors
Early Commercial Traction
Early product revenue and enrollment growth show initial demand, while reimbursement and coverage gains can support repeatable adoption. The expanding prescriber base and treatment-naive use indicate the launch is building a broader commercial foundation.
Read all positive factors
Crinetics Pharmaceuticals (CRNX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.99B
Dividend YieldN/A
Average Volume (3M)6.12M
Price to Earnings (P/E)―
Beta (1Y)1.57
Revenue Growth2928.45%
EPS Growth-22.68%
CountryUS
Employees594
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.05
Shares Outstanding106,065,230
10 Day Avg. Volume4,155,075
30 Day Avg. Volume6,124,660
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)4.41
Price to Sales (P/S)568.91
P/FCF Ratio-11.41
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$85.56Price Target Upside2.18% Upside
Rating ConsensusHold
Number of Analyst Covering14
EPS Forecast (FY)-4.61
Revenue Forecast (FY)$68.59M
Crinetics Pharmaceuticals Business Overview & Revenue Model
Company Description
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their fl...
How the Company Makes Money
Crinetics Pharmaceuticals does not have a broadly established commercial product portfolio and is primarily in the development stage; as a result, its recurring revenue from product sales is null. The company’s funding and reported revenue, when p...
Crinetics Pharmaceuticals Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 17, 2026
Earnings Call Sentiment Positive
The call communicated a strong early commercial launch for Palsonify with meaningful patient additions, encouraging reimbursement progress (≈70% reimbursed, >60% coverage), expanding prescriber footprint and robust pipeline advancement, all supported by a strong balance sheet. Offsetting these positives are elevated and rising R&D and operating expenses, limited disclosure of certain commercial conversion metrics, a remaining reimbursement gap (~30% of patients), appointment‑driven adoption constraints, and no firm timelines provided for several key pivotal readouts or international revenue. On balance, the positives around launch momentum, payer traction, prescriber growth and cash runway outweigh the operational and disclosure limitations.Positive Updates
Strong Early Commercial Launch
Palsonify generated $10.3M in net product revenue (total revenue $10.7M including $0.4M license) in Q1 and added 232 new patient enrollment forms during the quarter, demonstrating early commercial traction.
Negative Updates
Rising R&D Spend and High Operating Investment
Research & development expense increased to $100.1M in Q1 from $85.1M in Q4 (increase of ~$15M, ~17.6% quarter‑over‑quarter), contributing to a high cash burn profile consistent with the ~$600M–$650M GAAP expense guidance for 2026.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Early Commercial Launch
Palsonify generated $10.3M in net product revenue (total revenue $10.7M including $0.4M license) in Q1 and added 232 new patient enrollment forms during the quarter, demonstrating early commercial traction.
Read all positive updates
Company Guidance
The company maintained 2026 guidance, forecasting GAAP operating expenses of $600–$650 million and non‑GAAP operating expenses (excluding cost of product revenue, stock‑based compensation, depreciation and amortization) of $480–$520 million, and said its $1.3 billion in cash, cash equivalents and investments provide runway into 2030. In Q1 Crinetics reported $10.7 million total revenue (including $10.3 million net product revenue and $0.4 million licensing), cost of product revenue of $0.2 million (would have risen by <$0.1M if prior 0‑cost inventory were included), R&D of $100.1 million (vs. $85.1M in Q4) and SG&A of $50.8 million (vs. $53.7M in Q4); shares outstanding were ~105.4M basic and ~123.5M fully diluted as of April 23, 2026. On the commercial front the launch added 232 new patient enrollment forms in Q1, about 70% of patients on therapy were reimbursed at quarter‑end, the company has achieved >60% coverage and remains on track to exceed its 75% coverage goal by end‑Q3 2026, and management expects low discontinuation with patient counts compounding over time.Crinetics Pharmaceuticals Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
72
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 42.16M | 7.70M | 1.04M | 4.01M | 4.74M | 1.08M |
| Gross Profit | 41.80M | 6.62M | 1.04M | 4.01M | 4.74M | 1.08M |
| EBITDA | -508.79M | -461.25M | -295.62M | -213.43M | -162.94M | -106.72M |
| Net Income | -501.61M | -465.32M | -298.41M | -214.53M | -163.92M | -107.64M |
Balance Sheet | ||||||
| Total Assets | 1.32B | 1.14B | 1.43B | 635.35M | 352.18M | 351.01M |
| Cash, Cash Equivalents and Short-Term Investments | 1.21B | 1.03B | 1.35B | 558.55M | 334.43M | 333.71M |
| Total Debt | 47.19M | 48.54M | 51.72M | 51.73M | 3.08M | 4.01M |
| Total Liabilities | 129.92M | 143.41M | 109.79M | 96.25M | 35.85M | 19.07M |
| Stockholders Equity | 1.19B | 992.08M | 1.32B | 539.11M | 316.33M | 331.94M |
Cash Flow | ||||||
| Free Cash Flow | -425.18M | -383.68M | -229.81M | -171.00M | -116.86M | -89.02M |
| Operating Cash Flow | -422.51M | -377.92M | -225.97M | -166.31M | -115.20M | -88.59M |
| Investing Cash Flow | -4.15M | 173.91M | -574.82M | -200.41M | -173.98M | -56.48M |
| Financing Cash Flow | 427.92M | 40.61M | 1.01B | 388.94M | 121.96M | 252.68M |
Crinetics Pharmaceuticals Technical Analysis
Positive
83.73
Price Trends
66.85
Positive
52.19
Positive
48.75
Positive
Market Momentum
4.02
Positive
89.74
Negative
93.22
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRNX, the sentiment is Positive. The current price of 83.73 is below the 20-day moving average (MA) of 84.10, above the 50-day MA of 66.85, and above the 200-day MA of 48.75, indicating a bullish trend. The MACD of 4.02 indicates Positive momentum. The RSI at 89.74 is Negative, neither overbought nor oversold. The STOCH value of 93.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRNX.
Crinetics Pharmaceuticals Risk Analysis
Crinetics Pharmaceuticals disclosed 81 risk factors in its most recent earnings report. Crinetics Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Crinetics Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $5.73B | 29.04 | 20.06% | ― | 54.89% | ― | |
59 Neutral | $10.09B | -39.17 | -21.50% | ― | 134.84% | 6.73% | |
56 Neutral | $8.99B | -16.77 | -44.22% | ― | 2928.45% | -22.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $2.51B | -4.49 | 392.35% | ― | 17.50% | -5.66% |
* Healthcare Sector Average
CRNX
Crinetics Pharmaceuticals
84.69
55.29
188.06%
LGND
Ligand Pharma
287.39
130.08
82.69%
RARE
Ultragenyx Pharmaceutical
25.32
-4.20
-14.23%
KYMR
Kymera Therapeutics
127.31
84.72
198.92%
Crinetics Pharmaceuticals Corporate Events
Financial DisclosuresLegal ProceedingsM&A TransactionsShareholder Meetings
Crinetics Faces Shareholder Challenges to Vertex Merger Deal
Negative
Aug 19, 2026
On July 6, 2026, Crinetics agreed to be acquired by Vertex Pharmaceuticals via a merger that would value Crinetics’ equity at about $10 billion, with shareholders scheduled to vote on the deal at a special meeting on August 28, 2026. Since C...
M&A TransactionsRegulatory Filings and ComplianceShareholder Meetings
Crinetics nears shareholder vote on Vertex merger
Positive
Aug 14, 2026
On July 6, 2026, Crinetics Pharmaceuticals agreed to merge with Vertex Pharmaceuticals through a transaction in which Crinetics will become a wholly owned subsidiary of Vertex. The deal is structured via a merger of Clark Merger Sub, Inc. into Cri...
Business Operations and StrategyM&A TransactionsRegulatory Filings and Compliance
Crinetics Pharmaceuticals Announces Merger Agreement With Vertex
Positive
Jul 10, 2026
On July 6, 2026, Crinetics Pharmaceuticals entered into a Merger Agreement under which Clark Merger Sub, a wholly owned subsidiary of Vertex Pharmaceuticals, will merge into Crinetics, with Crinetics surviving as a wholly owned subsidiary of Verte...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Vertex to Acquire Crinetics in $10 Billion Merger
Positive
Jul 6, 2026
On July 6, 2026, Vertex Pharmaceuticals and Crinetics Pharmaceuticals signed a definitive merger agreement under which Vertex will acquire Crinetics for $85 per share in cash, valuing the company at about $10 billion, or $8.8 billion net of estima...
Executive/Board ChangesShareholder Meetings
Crinetics Shareholders Endorse Board, Auditor and Executive Pay
Positive
Jun 22, 2026
Crinetics Pharmaceuticals held its annual meeting of stockholders online via live audio webcast on June 18, 2026, with approximately 97% of eligible common shares represented. Shareholders elected three Class II directors—Caren Deardorf, Wes...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.